CA3077678A1 - Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy - Google Patents

Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy Download PDF

Info

Publication number
CA3077678A1
CA3077678A1 CA3077678A CA3077678A CA3077678A1 CA 3077678 A1 CA3077678 A1 CA 3077678A1 CA 3077678 A CA3077678 A CA 3077678A CA 3077678 A CA3077678 A CA 3077678A CA 3077678 A1 CA3077678 A1 CA 3077678A1
Authority
CA
Canada
Prior art keywords
drug product
patients
prednisone
zytiga
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3077678A
Other languages
English (en)
French (fr)
Inventor
Namphuong TRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Oncology Inc
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of CA3077678A1 publication Critical patent/CA3077678A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3077678A 2017-10-11 2018-02-08 Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy Pending CA3077678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11
US62/570,781 2017-10-11
PCT/US2018/017438 WO2019074536A1 (en) 2017-10-11 2018-02-08 METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY

Publications (1)

Publication Number Publication Date
CA3077678A1 true CA3077678A1 (en) 2019-04-18

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3077678A Pending CA3077678A1 (en) 2017-10-11 2018-02-08 Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy

Country Status (16)

Country Link
US (2) US20190105332A1 (enExample)
EP (1) EP3694604A1 (enExample)
JP (1) JP2020536903A (enExample)
KR (1) KR20200068689A (enExample)
CN (1) CN111542373A (enExample)
AU (1) AU2018347804A1 (enExample)
BR (1) BR112020007090A2 (enExample)
CA (1) CA3077678A1 (enExample)
EA (1) EA202090916A1 (enExample)
IL (1) IL273826A (enExample)
JO (1) JOP20200072A1 (enExample)
MA (1) MA50341A (enExample)
MX (1) MX2020003830A (enExample)
PH (1) PH12020550151A1 (enExample)
UA (1) UA124865C2 (enExample)
WO (1) WO2019074536A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Also Published As

Publication number Publication date
KR20200068689A (ko) 2020-06-15
EA202090916A1 (ru) 2020-12-11
BR112020007090A2 (pt) 2020-09-24
AU2018347804A1 (en) 2020-04-16
UA124865C2 (uk) 2021-12-01
MX2020003830A (es) 2020-11-06
JOP20200072A1 (ar) 2020-04-29
IL273826A (en) 2020-05-31
PH12020550151A1 (en) 2021-02-08
WO2019074536A1 (en) 2019-04-18
MA50341A (fr) 2020-08-19
CN111542373A (zh) 2020-08-14
JP2020536903A (ja) 2020-12-17
US20190105332A1 (en) 2019-04-11
US20200069704A1 (en) 2020-03-05
EP3694604A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP7201694B2 (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
JP2024510612A (ja) ソトラシブ投与レジメン
US20200069704A1 (en) Methods Of Treating Prostate Cancer
US20190262330A1 (en) Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
KR20210153038A (ko) 전이성 거세-민감성 전립선암의 치료를 위한 항안드로겐
KR20240083178A (ko) Kras g12c 돌연변이를 포함하는 암의 치료를 위한 소토라십 및 egfr 항체
TW202302084A (zh) 以安森司坦和帕博西尼治療乳癌
US20250177414A1 (en) Combination therapies for treatment of breast cancer
WO2025027138A9 (en) Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer
HK40116445A (en) Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2023209555A1 (en) Approved drug products and methods for treating prostate cancer
CN117580572A (zh) 用安森司坦和帕博西尼治疗乳腺癌
JP2025506402A (ja) 転移性去勢抵抗性前立腺癌及びｈｒｒ変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン＋プレドニゾン
WO2020144650A1 (en) Anti-androgens for the treatment of prostate cancer
EA046078B1 (ru) Антиандрогены для лечения метастатического кастрационно-чувствительного рака предстательной железы
WO2014193589A1 (en) Cancer treatment method

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220602

EEER Examination request

Effective date: 20220602

EEER Examination request

Effective date: 20220602